Treatments and Severe Outcomes for Patients Diagnosed With MIS-C at Four Children's Hospitals in the United States, March 16, 2020-March 10, 2021.

ABSTRACT:

Background

Clinical management of multisystem inflammatory syndrome in children (MIS-C) has varied over time and by medical institution.

Methods

Data on patients with MIS-C were collected from 4 children's hospitals between March 16, 2020 and March 10, 2021. Relationships between MIS-C treatments and patient demographics, clinical characteristics, and outcomes were described. Propensity score matching was utilized to assess the relative risk of outcomes dependent on early treatment with intravenous immunoglobulin (IVIG) or low-dose steroids, controlling for potential confounding variables.

Results

Of 233 patients diagnosed with MIS-C, the most commonly administered treatments were steroids (88.4%), aspirin (81.1%), IVIG (77.7%) and anticoagulants (71.2%). Compared wit

SUBMITTER: Shah AB 

PROVIDER: S-EPMC11318085 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature